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Abstract
Background—False-positive mammography results are common. Biennial screening may
decrease the cumulative probability of false-positive results across many years of repeat screening
but could also delay cancer diagnosis.
Objective—To compare the cumulative probability of false-positive results and the stage
distribution of incident breast cancer after 10 years of annual or biennial screening mammography.
Design—Prospective cohort.
Setting—Seven mammography registries in the National Cancer Institute–funded Breast Cancer
Surveillance Consortium.
Participants—169,456 women who received a first screening mammogram at age 40–59
between 1994 and 2006 and 4,492 women with an incident invasive breast cancer diagnosed
between 1996 and 2006.
Measurements—False-positive recalls and biopsy recommendations; stage distribution of
incident breast cancer.
Results—False-positive recall probability was 16.3% at first and 9.6% at subsequent
mammography. False-positive biopsy recommendation probability was 2.5% at first and 1.0% at
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subsequent examinations. Availability of comparison films halved the odds of a false-positive
recall (adjusted OR 0.50 (CI 0.45, 0.56)). When screening began at age 40, the cumulative
probability of a woman receiving at least one false-positive recall after 10 years was 61.3% (95%
CI, 59.4% to 63.1%) with annual and 41.6% (CI, 40.6% to 42.5%) with biennial screening.
Cumulative probability of false-positive biopsy recommendation was 7.0% (CI, 6.1% to 7.8%)
with annual and 4.8% (CI, 4.4% to 5.2%) with biennial screening. Estimates were comparable
when screening began at age 50. We observed a non-statistically significant increase in the
proportion of late-stage cancers with biennial compared to annual screening (absolute increase
3.3% (CI −1.1, 7.8) age 40–49, 2.3% (CI −1.0, 5.7) age 50–59) among a population of women
with incident breast cancer.
Limitations—Few women underwent screening over the entire 10 year period. Radiologist
characteristics influence recall rates and were unavailable. Most mammograms were film rather
than digital exams. Incident cancers were analyzed in a small population of women who
developed cancer.
Conclusions—After 10 years of annual screening, more than half of women will receive at least
one false-positive recall, and 7–9% will receive a false-positive biopsy recommendation. Biennial
screening appears to reduce the cumulative probability of false-positive results after 10 years but
may be associated with a small absolute increase in the probability of being diagnosed with late
stage cancer.
INTRODUCTION
Mammography is the only screening test shown to reduce breast cancer mortality in clinical
trials (1–5). However, screening a healthy population confers both harms and benefits.
False-positive (FP) recalls for additional imaging after screening mammography occur for
14% of women at first screening and for 8% at subsequent exams (2, 6), causing many
women inconvenience and anxiety. Recommendations for fine needle aspiration or surgical
biopsy after screening mammography are less common (2) but have more severe
consequences (7, 8).
Women will undergo 12 screening mammography examinations in their lifetimes if,
following updated U.S. Preventive Services Task Force guidelines, they start biennial
screening at age 50 and stop at age 74 (9). They will undergo 17 examinations if they start
biennial screening at age 40, 24 if they start annual screening at age 50, and 34 if they start
annual screening at age 40. Estimates of the probability that a woman will experience at
least one FP recall after 10 screening examinations range from 29% to 77% (10–12), and are
about 8–9% for benign biopsy (12, 13). These estimates, however, are based on
extrapolations, are limited by statistical methodology that assumes women participating in
multiple screening rounds are representative of all women recommended for screening, and
do not take into account factors shown in prior studies to be associated with wide variability
in FP rates, such as radiologist recall rates (14–17) and patient age, breast density, hormone
therapy use, and screening interval (6, 15, 18).
To address these limitations, we estimated the cumulative probability of FP recall and
biopsy recommendation after 10 years of annual or biennial screening using data from the
National Cancer Institute–funded Breast Cancer Surveillance Consortium (BCSC) (19), a
nationally representative longitudinal sample of screening mammograms from community
practice, and using newer statistical methods that account for duration of observation and
informative censoring (20). In addition, we aimed to estimate how patient characteristics and
variability in radiologist FP rates might affect cumulative FP probability, and compared the
stage at diagnosis of incident breast cancers among women whose preceding screening
interval was approximately biennial or annual.
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We used data from seven BCSC mammography registries
(http://breastscreening.cancer.gov) (19) (see Appendix A). Registries collected patient
characteristics and clinical information at each mammogram, including radiologists’
assessments and recommendations based on the American College of Radiology’s Breast
Imaging Reporting and Data System (BI-RADS®) (21). Each registry is linked to a state
cancer registry or regional Surveillance, Epidemiology, and End Results (SEER) program,
which we used to determine cancer status following mammography. Six of seven sites also
linked to pathology databases. Data were pooled at a central Statistical Coordinating Center.
Registries and the Coordinating Center received Institutional Review Board approval for
active or passive consenting processes or a waiver of consent to enroll participants, link
data, and perform analysis. All procedures were Health Insurance Portability and
Accountability Act compliant, and registries and the Coordinating Center received a Federal
Certificate of Confidentiality and other protection for the identities of women, physicians,
and facilities.
In analyses of FP probabilities we included women who were age 40–59 at first screening
mammogram performed at a participating BCSC facility. Mammograms were considered
screening exams if the radiologist indicated routine screening. To avoid misclassifying
diagnostic mammograms as screening exams, we excluded mammograms when a breast-
imaging exam occurred within the prior nine months. We included screening mammograms
from 1994 to the most recent year with complete breast cancer capture, which varied from
2004 to 2007 across the seven registries.
A separate cohort was constructed for analyses of cancer stage, which included women age
40–59 at the time of diagnosis of an incident invasive breast cancer between 1996 and 2006,
at or following a screening mammogram and who had at least one additional prior
mammogram. We excluded women with cancer diagnoses between 1994 and 1996 to allow
for capture of mammography up to two years prior to diagnosis (for women undergoing
biennial screening). We also excluded women with cancer diagnoses at or after age 60 to
focus on incident cancers in 10-year periods similar to those in our analyses of cumulative
FP probability (ages 40–49 for women starting screening at age 40, 50–59 for women
starting screening at age 50). All breast cancers were classified according to the American
Joint Committee on Cancer (AJCC) staging system (22). Late-stage cancer was defined as
stage IIB, III, or IV. We also restricted our sample to women with breast cancer diagnoses
that occurred within a fixed follow-up period after each woman’s most recent prior
screening mammogram (the index mammogram): within 1 year for women with 9–18
months separating the index and next most recent prior mammograms (annual screeners);
and within 2 years for women with 19–30 months between the index and most recent prior
mammograms (biennial screeners). A flow diagram summarizing inclusion and exclusion
criteria for the cancer cohort is provided in Appendix B.
Measures and Definitions
Patient characteristics, including birth date, postmenopausal hormone therapy use, and
history of breast cancer in a first-degree relative, were collected by questionnaire at each
examination. We considered mammograms first examinations if there were no prior
mammograms in the BCSC database, no indication of comparison films, and no self-report
of a prior mammogram. We defined screening intervals using women’s self-report and
information from the BCSC database on the date of the prior screening mammogram.
Screening interval was categorized into annual (9–18 months), biennial (19–30 months), or
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longer than biennial (>30 months). We censored 4,323 (2.5%) of women whose self-
reported time since last mammogram differed from that in the database by more than six
months, to ensure that women had not obtained a mammogram outside of the BCSC, and we
used database-derived time since last mammogram when discrepancies of less than six
months occurred. We also censored women at time of cancer diagnosis or the end of the
study.
Recall was defined as a BI-RADS assessment for the initial screening mammogram (initial
assessment) of 0 (needs additional imaging evaluation); 4 (suspicious abnormality); 5
(highly suggestive of malignancy); or 3 (probably benign finding) with a recommendation
for immediate follow-up.
Biopsy recommendation was defined as a final BI-RADS assessment of 4 or 5, or 0 or 3
with a recommendation for biopsy, fine needle aspiration, or surgical consult after all
imaging workup and within 90 days of the screening exam (final assessment) (23). Final BI-
RADS assessments were set to missing and the exam was excluded from biopsy
recommendation analyses if the screening exam was performed at a facility that does not
capture follow-up exams or if the final assessment was 0 with recommendation for
additional imaging, non-specified workup, or a missing recommendation (N = 25,045,
6.5%).
A recall or biopsy recommendation was considered false-positive when there was no
diagnosis of invasive carcinoma or ductal carcinoma in situ within 1 year of the screening
examination or before the next screening mammogram, whichever occurred first.
For our analyses of breast cancer stage, we defined the screening interval (annual or
biennial) associated with cancer diagnosis as the interval between screening mammograms
immediately preceding the diagnosis, specifically the interval between a woman’s most
recent screening mammogram prior to the date of cancer diagnosis (index mammogram) and
the screening mammogram before that exam. This approach is described in a previous
publication (24).
Statistical Analysis
The proportion of mammograms resulting in a FP recall or biopsy recommendation at a
single screening was computed for first and subsequent screening rounds. Generalized linear
mixed models estimated the effect of age, family history of breast cancer, breast density
estimated using density categories defined by the BI-RADS Atlas, postmenopausal hormone
therapy use, and year of first exam on odds of a mammogram resulting in a FP result at a
single screening round, while accounting for BCSC registry and random variation among
radiologists. Models for FP results at subsequent rounds also adjusted for availability of
comparison films and time since previous mammography. Adjusted FP probabilities were
estimated from these models using indirect standardization (25, 26).
We used data from women age 40–59 at first mammography to build a model for the
probability of FP results at each screening round using generalized linear mixed models for
FP results conditional on screening round number, total number of screening rounds before
censoring, the covariates adjusted for in analyses of single screening rounds, and
interpreting radiologist. We then used this to model to estimate the cumulative probability of
FP results for a woman who begins screening at age 40 or age 50 after 10 years of screening,
by aggregating probabilities at individual screening rounds to the individual woman level.
We used the method of Hubbard et al. (20), which accounts for the informative censoring
which may arise when the length of time that a subject is under observation is associated
with the outcome. We assumed that covariate effects were the same at each screening round,
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except for screening interval, which was assumed to have no effect at the first screening
round and age, which was allowed to have a differing effect at first and subsequent
screening rounds. We used indirect standardization to ensure a common distribution of
BCSC registries across risk profiles (25, 26). We also report unadjusted estimates that do not
account for covariates or between-radiologist variation. Appendix C has method details for
estimating cumulative FP probabilities.
We report fitted values from our model for combinations of covariates chosen to represent a
range of patient characteristics (age, year, hormone therapy use, family history of breast
cancer, breast density, registry at the time of their first screening exams) for risk categories
of low (no family history of breast cancer, BI-RADS 1 breast density), intermediate (no
family history of breast cancer, BI-RADS 2 breast density), high (no family history of breast
cancer, BI-RADS 3 breast density), and very high (family history of breast cancer, BI-
RADS 3 breast density) and for quartiles of the distribution of radiologist FP rates. We
defined the risk categories in terms of family history and BI-RADS breast density based on
the results of previous studies of factors associated with FP results (15, 18). All risk profiles
are for women who used no postmenopausal hormone therapy and had comparison films
available for all subsequent exams. Quartiles for radiologist FP rates were constructed based
on radiologist random effects from the FP risk models.
For invasive cancers, we estimated adjusted probabilities of each cancer stage and late-stage
cancer using logistic regression models stratified by age at diagnosis (40–49 and 50–59) and
including covariates for screening interval, race, family history, and BCSC registry. This set
of adjustment variables was selected on the basis of prior research into the relationship
between screening interval and risk of late stage cancer (24).
We defined statistical significance using a two-sided alpha-level of 0.05. Analyses were
performed in R 2.10.1 (R Foundation for Statistical Computing, Vienna, Austria).
Role of the Funding Source
The National Cancer Institute supported this project through the BCSC cooperative
agreements. All study authors and members of the BCSC Steering Committee approved the
final version of the manuscript. The authors had full responsibility in designing the study,
collecting the data, analyzing and interpreting the data, deciding to submit the manuscript
for publication, and writing the manuscript.
RESULTS
We included 386,799 mammograms from 169,456 women interpreted by 997 radiologists.
Nearly half the women (47.7%) had only 1 screening mammogram; 11.8% had 5 or more
examinations (Table 1). The complete distribution of observed numbers of rounds of
screening and patterns of screening intervals are provided in Appendix D. In our cohort,
9,331 women (5.5%) had only one year of follow-up, and 4,891 (2.9%) were observed for
10 or more years.
Most mammograms (78.9%) were for women aged 40–49 years at first mammogram.
Median age at first screening was 42 for women who began screening in their forties and 53
for women who began in their fifties. Among subsequent mammograms, 55.6% occurred at
an approximately annual screening interval (within 9–18 months of a prior mammogram)
and 27.6% occurred approximately biennially (within 18–30 months of a prior
mammogram). The remainder of mammograms occurred at longer than biennial intervals.
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Most mammograms were assessed as negative (BI-RADS 1) or benign (BI-RADS 2); a BI-
RADS score of 0, indicating need for additional imaging, was the third most common initial
assessment for first and second mammograms and both age strata (Table 1). Of the 44,992
mammograms with initial BI-RADS scores of 0 across all observed screening rounds, most
(71.5%) resolved to negative or benign readings; 12.3% remained a BI-RADS 0, 10.1% had
suspicious abnormalities, and data were missing for 6.0% (Appendix E).
Probability of a Mammogram Leading To False-Positive Recall or Biopsy Recommendation
Unadjusted FP recall probability was 16.3% for first and 9.6% for subsequent
mammograms. FP recall probabilities were higher for mammograms among women who
started screening more recently, those with heterogeneously dense breasts, and in first exams
only, older women and those with a family history of breast cancer (Table 2). Availability of
comparison films halved the odds of FP recall on subsequent screening exams (odds ratio
[OR], 0.50; 95% CI, 0.45 to 0.56), and biennial screening interval (last exam within 19–30
months) increased the risk of FP recall relative to an annual interval (within 9–18 months)
(OR, 1.13; CI, 1.08 to 1.19).
Unadjusted FP biopsy recommendation probability was 2.5% for first and 1.0% for
subsequent exams. FP biopsy recommendation probabilities were higher for older women
and those with heterogeneously dense breasts and in first exams only, higher for those with a
family history of breast cancer (Table 3).
Cumulative Probability of a Woman Experiencing a False-Positive Recall or Biopsy
Recommendation After 10 Years of Screening
For a woman who starts screening at age 40 the unadjusted cumulative probability of a FP
recall after 10 years of screening was 61.3% (CI, 59.4% to 63.1%) with annual and 41.6%
(CI, 40.6% to 42.5%) with biennial screening (Table 4). For a woman who starts screening
at age 50, the unadjusted probability was 61.3% (CI, 58.0% to 64.7%) under annual and
42.0% (CI, 40.4% to 43.7%) under biennial screening.
The adjusted cumulative probability of a FP recall under biennial screening was less than
that under annual screening for each risk profile we modeled (Table 4). For women at
intermediate risk of having FP recall (no family history of breast cancer, BI-RADS density
2) who start screening at age 40 and whose films are read by a radiologist with a median FP
recall rate, for example, we estimated the cumulative probability of a FP recall after 10 years
of biennial screening to be 37.8% compared to 52.4% for annual screening. Estimated
reductions in cumulative FP probabilities with biennial compared to annual screening were
comparable for women who began screening at age 50.
Estimates of a woman’s adjusted cumulative probability of experiencing a FP recall after 10
years of screening increased across FP risk profiles, radiologists’ recall rates, and annual
compared to biennial screening (Table 4). Within each stratum of FP risk, radiologist risk,
and screening frequency, 10-year risk of there was little difference in FP recall associated
with age at first mammogram (e.g. 29.4% for low FP risk, low radiologist risk, annual
screening begun at age 40, compared to 32.4% for low FP risk, low radiologist risk, annual
screening begun at age 50).
Estimates of a woman’s adjusted cumulative probability of experiencing a FP biopsy
recommendation after 10 years of screening increased across FP risk profiles and with
increasing radiologists’ FP biopsy recommendation rates (Table 5). Probabilities were
higher with annual compared to biennial screening and for older (starting age 50) compared
to younger ages (starting age 40) at first mammogram.
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At their first screening mammogram, 6.5% of BCSC women had BI-RADS 1 breast density
and reported no family history of breast cancer. After 10 years of screening, these women
would be expected to have cumulative FP probabilities similar to those of the low FP risk
profile. In the BCSC sample, 37.1% had BI-RADS 2 breast density and reported no family
history of breast cancer, like the intermediate FP risk profile; 39.2% had BI-RADS 3 breast
density and reported no family history of breast cancer, like the high FP risk profile; and
3.7% had BI-RADS 3 breast and reported a family history of breast cancer, like the very
high FP risk profile. The remainder of the BCSC sample had characteristics not reflected by
the example risk profiles reported in Tables 4 and 5.
Incident Cancers
We identified 4,492 women with an incident invasive breast cancer diagnosis at age 40–59
following an annual or biennial screening interval (Appendix B). After adjusting for family
history, race, and BCSC registry, a non-statistically significantly greater proportion of
women who were screened biennially were diagnosed with a late-stage cancer (24.6% v.
21.3%, absolute difference 3.3% (−1.1, 7.8) for women age 40–49; 24.6% v. 21.9%,
absolute difference 2.3; CI −1.0 to 5.7 for women age 50–59) (Table 6). Odds ratios for
model covariates are in Appendix F.
DISCUSSION
In an analysis of probabilities of false-positive recall or biopsy recommendation using
registry data collected in community practice, we estimated that the risk of a FP result was
higher following a biennial screening interval than an annual interval. However, after 10
years of repeat screening at approximately annual or biennial intervals, the cumulative
probability of receiving at least one FP recall or biopsy recommendation was lower with
biennial compared to annual screening whether women started screening at age 40 or age 50.
Compared to annual screening, biennial screening was associated with a non-statistically
significant absolute increase of 2 and 3 percent in the proportion of women diagnosed with
late-stage cancer in a cohort of those who developed cancer.
Our estimates of a woman’s cumulative probability of a FP mammogram result after repeat
screening are higher than previously reported (10, 11, 13, 15). This is partly explained by a
higher probability of FP results at each exam for our cohort. Our estimate of the FP recall
probability at a single screening round was 16.3% at first exam and 9.6% at subsequent
exams, compared to estimates of 6.5% for other cohorts (10). Additionally, previous
methods to estimate the cumulative FP probability assumed that censoring was non-
informative, which leads to underestimation if women at higher risk of a FP are more likely
to be observed for fewer screening rounds (20).
Our analysis identified covariates associated with FP mammography results that resemble
previous reports. Positive associations between FP recall and previous breast biopsies,
family history of breast cancer, postmenopausal hormone therapy use, more recent exam
year, and time between screening exams have been reported previously, as have negative
associations between FP recall and older age and comparison film availability (6, 15, 18,
27–29). We also identified statistically significant associations between FP recall and family
history of breast cancer, exam year, time since previous mammogram, and availability of
comparison films. Surprisingly, we found older age was associated with FP recall only at the
first exam. This induced small differences in the cumulative probability of FP recall by
starting age.
Few previous studies have estimated the cumulative probability of FP mammography results
after repeat screening in U.S. community practice. We searched PubMed Central using the
Hubbard et al. Page 7













terms “cumulative”, “false positive”, and “mammography” to identify all studies evaluating
the cumulative probability of FP recall and biopsy recommendation after repeat screening
mammography. From among these, we reviewed the titles and abstracts to identify all
studies providing estimates of the cumulative FP probability based on screening
mammography in the U.S. We then searched all references citing these papers using Web of
Science and reviewed titles and abstracts of these manuscripts to identify any additional
references we may have missed. This review found 7 studies reporting cumulative FP
probabilities for repeat screening mammography in the U.S (10–13, 15, 20, 30). Elmore
(1998) reported a 49.1% probability after 10 rounds of screening (10). Christiansen (2000)
found a FP probability of 22% after five screening mammograms under biennial screening
for an intermediate-risk woman and median radiologist (15), compared to estimates for our
population of 38–40%. Studies of benign biopsy have found a probability of 8–9% after 10
screening rounds (12, 13), which are similar to our estimate. Based on our review, we
believe ours is the first study to incorporate covariate effects and variation among
radiologists into estimates of cumulative FP biopsy recommendation rates.
Our results on the risk of late-stage cancer following annual and biennial screening intervals
are similar to those previously reported. A previous BCSC study found a statistically
significantly higher proportion of late-stage cancers among women 40–49 participating in
biennial compared to annual screening (28% vs. 21%), but no significant difference among
women 50–59 (22% vs. 21%) (24). Although we found no statistically significant absolute
difference in the overall proportion of late-stage cancers with biennial compared to annual
screening, our findings could not exclude an increase in late stage cancer of as much as
7.8% among women in their 40s and as much as 5.7% among women in their 50s based on
the upper confidence bound of the estimate of absolute difference. The relatively broad
confidence limits around our estimates of difference are likely attributable to the small
sample size available for our analysis of incident cancer, and a larger future study is required
to exclude the possibility of a clinically significant increase in late stage cancer with biennial
compared to annual screening, or even a smaller and less clinically significant decrease.
We have investigated two types of FP mammography results: recall for additional imaging
and recommendation for biopsy. Our definitions of FP recall and biopsy recommendation
are consistent with the BI-RADS Atlas, which distinguishes these two types of false-
positives (21). Previous research on the effects of FP mammograms suggests that women
receiving a FP recall or benign biopsy experienced elevated anxiety and distress (31).
Benign biopsy poses additional risks of pain and scarring (32, 33). So FP recalls, although
common, exert smaller effects than do FP biopsy recommendations. Both the relative
frequency and severity of these two types of FP results should be considered when
evaluating the harms of screening mammography.
Most screening mammograms had an initial assessment of negative or benign (BIRADS 1 or
2) or of BIRADS 0, needs additional imaging. Most in the latter category resolved on further
evaluation to a negative or benign result; about 10% were interpreted as having suspicious
abnormalities, and status continued to be unresolved (BIRADS 0) or was missing for about
19%. This could be because the woman did not return for follow-up imaging within 90 days
of her screening mammogram or because she went to a facility outside the BCSC. In our
analysis these observations have been defined as recalls but have been excluded from biopsy
recommendation analyses. If the sub-group with missing final assessments is likely to go on
to receive a biopsy recommendation, then this would tend to bias estimates of FP biopsy
recommendation downward. However, these missing observations make up only 6% of the
total sample, so the magnitude of this bias is expected to be small.
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Our study has limitations. Although it was based on a large sample, it included 10 or more
rounds of screening for a very small number of women, so our cumulative probability
estimates after 10 years of annual screening depend on statistical modeling. However we
were able to incorporate information from women with fewer than 10 exams using statistical
methods developed for this purpose that accommodate informative censoring; previous
methods for estimating cumulative FP probabilities are downwardly biased when FP recall
is more common among women with fewer observed rounds of screening, as in our cohort
(20).
We lacked information on radiologist characteristics associated with FP recall. Previous
research identified variation in interpretive performance by radiologist characteristics such
as fellowship training and years of experience as influencing FP recall (14, 16, 17, 34, 35).
We attempted to capture differences in radiologist FP rates using random effects to estimate
FP recall and biopsy recommendation variability in the middle 50% of radiologists.
Variation is even larger when comparing radiologists with the highest and lowest FP rates.
Most mammograms in this analysis were film-screen exams. Digital screening
mammography is rapidly becoming the predominant screening modality, with 76.2% of
accredited facilities using full field digital machines as of May 1, 2011 (36). However,
research on the performance of digital mammography has indicated similar specificity, and
hence FP rates, for digital and film-screen exams (37, 38). A slight, non-statistically
significant decrease in specificity has been observed for some sub-groups (38). This would
result in increased FP probabilities relative to those observed in this study.
The study’s cumulative FP risk estimates apply only to the first 10 years of screening. Over
the course of a lifetime of screening, beginning screening 10 years earlier would result in an
additional 10 screening mammograms under annual screening and 5 under biennial, and the
lifetime risk of FP mammography results will thereby be increased. We could not estimate
lifetime cumulative FP risks because doing so would require extrapolation beyond the length
of observation in the current study. We found no statistical difference in FP recall
probabilities among women age 60 and over and those aged 40–44 years, but estimated that
FP biopsy recommendation probabilities were statistically significantly higher in women age
65 or older. Therefore, cumulative FP biopsy recommendation probabilities for the ten years
beginning at age 60 might be higher than those we have reported for women who began
screening at younger ages.
In summary, we estimate that after 10 years of annual screening, a majority of women will
receive at least one FP recall, and 7–9% will receive a FP biopsy recommendation. Both
probabilities are lowered with biennial screening. In a population of women diagnosed with
cancer, we also identified a non-statistically significant increase in the proportion diagnosed
with late stage cancer after biennial screening compared to annual. Biennial screening thus
decreases risks but may also attenuate the benefits of routine screening. Women and
physicians should be aware of the possibility of these harms associated with different
screening intervals so they can make informed decisions about screening and be prepared for
what to expect when they receive their results. They should also ensure that prior
mammograms, when they exist, are available to the interpreting radiologist, as it seems clear
from these data that availability of prior studies may halve the odds of a FP recall.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Characteristics of Women Aged 40–49 and 50–59 Years at Time of First Mammographic Screening, Stratified
By First or Second Exam.*









Total 135,604 33,852 70,740 17,886
Family history of breast cancer
  Yes 7,089 (5.2) 2,181 (6.4) 4,601 (6.5) 1,410 (7.9)
  No 108,346 (79.9) 25,877 (76.4) 56,430 (79.8) 13,447 (75.2)
  Missing 20,169 (14.9) 5,794 (17.1) 9,709 (13.7) 3,029 (16.9)
BI-RADS† breast density
  Almost entirely fat 5,537 (4.1) 2,693 (8.0) 2,825 (4.0) 1,431 (8.0)
  Scattered fibroglandular densities 35,372 (26.1) 11,823 (34.9) 19,930 (28.2) 6,768 (37.8)
  Heterogeneously dense 43,698 (32.2) 8,115 (24.0) 24,407 (34.5) 4,639 (25.9)
  Extremely dense 11,225 (8.3) 1,286 (3.8) 5,810 (8.2) 720 (4)
  Missing 39,772 (29.3) 9,935 (29.3) 17,768 (25.1) 4,328 (24.2)
Current hormone therapy use
  Yes 7,292 (5.4) 5,309 (15.7) 5,991 (8.5) 4,071 (22.8)
  No 111,777 (82.4) 21,673 (64.0) 56,902 (80.4) 10,826 (60.5)
  Missing 16,535 (12.2) 6,870 (20.3) 7,847 (11.1) 2,989 (16.7)
Time since last mammogram
  9–18 months -- -- 28,198 (39.9) 8,247 (46.1)
  19–30 months -- -- 22,659 (32) 5,116 (28.6)
  >30 months -- -- 19,883 (28.1) 4,523 (25.3)
Comparison film available
  Yes -- -- 53,717 (75.9) 12,286 (68.7)
  No -- -- 4,780 (6.8) 1,503 (8.4)
  Missing -- -- 12,243 (17.3) 4,097 (22.9)
Year of exam
  <1997 16,162 (11.9) 6,893 (20.4) 1,251 (1.8) 1,009 (5.6)
  1997–1999 41,269 (30.4) 11,503 (34) 13,477 (19.1) 5,281 (29.5)
  2000–2001 27,001 (19.9) 5,966 (17.6) 16,487 (23.3) 4,185 (23.4)
  2002–2004 33,231 (24.5) 6,484 (19.2) 25,678 (36.3) 5,158 (28.8)
  >2004 17,941 (13.2) 3,006 (8.9) 13,847 (19.6) 2,253 (12.6)
Initial BI-RADS assessment
  1: Negative 90,505 (66.7) 22,065 (65.2) 48,592 (68.7) 12,443 (69.6)
  2: Benign finding(s) 18,518 (13.7) 4,381 (12.9) 13,944 (19.7) 3,650 (20.4)
  3: Probably benign 3,989 (2.9) 1,409 (4.2) 573 (0.8) 191 (1.1)
  0: Needs additional imaging evaluation 21,205 (15.6) 5,513 (16.3) 7,224 (10.2) 1,488 (8.3)
  4: Suspicious abnormality 514 (0.4) 195 (0.6) 138 (0.2) 51 (0.3)
  5: Highly suggestive of malignancy 21 (0) 12 (0) 3 (0) 1 (0)
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  Missing 851 (0.6) 277 (0.8) 266 (0.4) 62 (0.3)
Final BI-RADS assessment
  1: Negative 2,699 (2.0) 937 (2.8) 719 (1.0) 201 (1.1)
  2: Benign finding(s) 90,855 (67.0) 22,543 (66.6) 48,379 (68.4) 12,413 (69.4)
  3: Probably benign 21,824 (16.1) 5,184 (15.3) 14,809 (20.9) 3,830 (21.4)
  0: Needs additional imaging evaluation 9,376 (6.9) 2,876 (8.5) 1,967 (2.8) 472 (2.6)
  4: Suspicious abnormality 2,861 (2.1) 911 (2.7) 766 (1.1) 173 (1.0)
  5: Highly suggestive of malignancy 58 (0) 26 (0.1) 12 (0) 6 (0)
  Missing 7,931 (5.8) 1,375 (4.1) 4,088 (5.8) 791 (4.4)
Number of screening rounds observed per woman
  1 64,636 (47.7) 16,194 (47.8) -- --
  2 27,845 (20.5) 6,831 (20.2) -- --
  3 16,463 (12.1) 4,129 (12.2) -- --
  4 10,696 (7.9) 2,626 (7.8) -- --
  5+ 15,964 (11.8) 4,072 (12.0) -- --
*
Based on 169,456 women who received a first screening mammogram at age 40–59 between 1994 and 2006.
†
Breast Imaging Reporting and Data System.
‡
We present characteristics for women at their second screening exam here rather than for all subsequent screening rounds, as in Tables 2 and 3, to
present data more representative of the entire population of women who underwent > 1 screening round; presenting data for all subsequent rounds
here would skew characteristics toward women who underwent multiple screening rounds.
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Table 2
Adjusted False-Positive Recall Probabilities at First and Subsequent Exam by Associated Characteristics with
Odds Ratios and 95% Confidence Intervals.
First exam** Subsequent exam††
% False
positive





OR of a false-
positive recall
(95% CI)
Age at mammogram (y)
  40–44 16.4 1.0 (Ref) 8.9 1.0 (Ref)
  45–49 19.9 1.27 (1.21, 1.33) 9.4 1.07 (1.01, 1.12)
  50–54 21.4 1.39 (1.31, 1.47) 8.7 0.98 (0.92, 1.05)
  55–59 19.7 1.25 (1.15, 1.36) 8.0 0.89 (0.82, 0.97)
  60–64 -- -- 8.3 0.92 (0.83, 1.03)
  ≥65 -- -- 9.6 1.09 (0.89, 1.33)
Family history of breast cancer
  Yes 20.5 1.21 (1.13, 1.30) 8.8 0.98 (0.91, 1.05)
  No 17.6 1.0 (Ref) 8.9 1.0 (Ref)
BI-RADS‡ breast density
  Almost entirely fat 11.8 0.62 (0.56, 0.67) 3.7 0.45 (0.40, 0.50)
  Scattered fibroglandular densities 17.8 1.0 (Ref) 7.9 1.0 (Ref)
  Heterogeneously dense 19.3 1.11 (1.06, 1.16) 10.7 1.40 (1.33, 1.46)
  Extremely dense 15.5 0.85 (0.79, 0.91) 9.0 1.16 (1.08, 1.25)
Current hormone therapy use
  Yes 17.3 0.96 (0.90, 1.03) 9.3 1.05 (0.99, 1.12)
  No 17.8 1.0 (Ref) 8.9 1.0 (Ref)
Year of first exam
  <1997 13.6 1.0 (Ref) 8.6 1.0 (Ref)
  1997–1999 15.7 1.18 (1.07, 1.31) 8.8 1.02 (0.96, 1.08)
  2000–2001 17.5 1.35 (1.21, 1.50) 9.1 1.07 (1.00, 1.14)
  2002–2004 19.3 1.52 (1.37, 1.69) 9.5 1.12 (1.03, 1.21)
  >2004 20.7 1.67 (1.49, 1.86) 11.0 1.31 (1.10, 1.57)
Comparison film available
  Yes -- -- 8.7 0.50 (0.45, 0.56)
  No -- -- 15.8 1.0 (Ref)
Time since last mammogram
    9–18 months -- -- 8.3 1.0 (Ref)
    19–30 months -- -- 9.3 1.13 (1.08, 1.19)
    >30 months -- -- 10.7 1.33 (1.26, 1.40)
*





Breast Imaging Reporting and Data System.
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**
Estimates for first exams are based on data for 81,305 women.
††
Estimates for subsequent exams are based on data for 121,662 mammograms from 57,282 women.
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Table 3
Adjusted False-Positive Biopsy Recommendation Probabilities at First and Subsequent Exam by Associated
Characteristics with Odds Ratios and 95% Confidence Intervals.
First exam Subsequent exam
% False
positive





OR of a false-
positive biopsy
(95% CI)
Age at mammogram (y)
  40–44 2.0 1.0 (Ref) 0.8 1.0 (Ref)
  45–49 2.8 1.40 (1.24, 1.57) 0.9 1.19 (1.02, 1.39)
  50–54 3.5 1.75 (1.53, 2.00) 1.0 1.33 (1.11, 1.60)
  55–59 3.0 1.48 (1.23, 1.79) 1.0 1.27 (1.01, 1.59)
  60–64 -- -- 0.8 1.09 (0.79, 1.50)
  ≥65 -- -- 1.5 1.91 (1.15, 3.16)
Family history of breast cancer
  Yes 3.3 1.47 (1.25, 1.72) 0.8 0.91 (0.73, 1.12)
  No 2.3 1.0 (Ref) 0.9 1.0 (Ref)
BI-RADS‡ breast density
  Almost entirely fat 1.6 0.67 (0.54, 0.84) 0.4 0.53 (0.38, 0.76)
  Scattered fibroglandular densities 2.3 1.0 (Ref) 0.7 1.0 (Ref)
  Heterogeneously dense 2.6 1.12 (1.01, 1.24) 1.1 1.47 (1.28, 1.68)
  Extremely dense 2.3 0.98 (0.83, 1.16) 1.2 1.57 (1.28, 1.94)
Current hormone therapy use
  Yes 2.4 1.01 (0.86, 1.20) 0.9 1.01 (0.84, 1.22)
  No 2.4 1.0 (Ref) 0.9 1.0 (Ref)
Year of first exam
  <1997 2.2 1.0 (Ref) 0.8 1.0 (Ref)
  1997–1999 2.3 1.04 (0.82, 1.32) 1.0 1.14 (0.97, 1.35)
  2000–2001 2.3 1.07 (0.84, 1.37) 0.9 1.12 (0.92, 1.37)
  2002–2004 2.5 1.16 (0.91, 1.48) 0.8 0.95 (0.75, 1.21)
  >2004 2.4 1.09 (0.84, 1.42) 0.9 1.12 (0.62, 2.01)
Comparison film available
  Yes -- -- 0.9 0.70 (0.52, 0.93)
  No 1.3 1.0 (Ref)
Time since last mammogram
  9–18 months -- -- 0.8 1.0 (Ref)
  19–30 months -- -- 1.0 1.22 (1.05, 1.41)
  >30 months -- -- 1.3 1.60 (1.37, 1.86)
*





Breast Imaging Reporting and Data System.
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**
Estimates for first exams are based on data for 79,397 women.
††
Estimates for subsequent exams are based on data for 120,447 mammograms from 56,922 women.
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Table 4
Cumulative Probability and 95% Confidence Intervals for False-Positive Recall after 10 Years of Screening
under Four Screening Strategies (Start Age 40 vs. 50; Annual vs. Biennial Screening) by Radiologist’s and
Woman’s Risk Level for False Positives*
Age 40 at first mammogram Age 50 at first mammogram
Annual screener Biennial screener Annual screener Biennial screener
Overall 61.3 (59.4,63.1) 41.6 (40.6,42.5) 61.3 (58.0,64.7) 42.0 (40.4,43.7)
25th Percentile FP risk radiologist
  Low FP risk woman* 29.4 (26.5,32.3) 20.1 (18.3,21.9) 32.4 (27.7,37.1) 21.4 (19.0,23.8)
  Intermediate FP risk woman 45.4 (42.3,48.5) 32.2 (30.0,34.4) 49.3 (43.8,54.8) 34.0 (31.3,36.7)
  High FP risk woman 51.4 (48.1,54.7) 37.0 (34.6,39.4) 55.5 (49.8,61.2) 39.0 (35.9,42.1)
   Very high FP risk woman 54.4 (50.9,57.9) 39.4 (36.9,41.9) 58.5 (52.6,64.4) 41.5 (38.2,44.8)
50th Percentile FP risk radiologist
  Low FP risk woman 34.9 (31.8,38.0) 24.1 (21.9,26.3) 38.3 (33.2,43.4) 25.6 (22.9,28.3)
  Intermediate FP risk woman 52.4 (49.1,55.7) 37.8 (35.4,40.2) 56.5 (50.8,62.2) 39.8 (36.7,42.9)
  High FP risk woman 58.7 (55.4,62.0) 43.2 (40.7,45.7) 62.8 (57.1,68.5) 45.2 (41.9,48.5)
  Very high FP risk woman 61.7 (58.0,65.4) 45.8 (43.1,48.5) 65.8 (59.9,71.7) 47.9 (44.4,51.4)
75th Percentile FP risk radiologist
  Low FP risk woman 43.4 (39.7,47.1) 30.6 (28.1,33.1) 47.2 (41.3,53.1) 32.3 (29.2,35.4)
  Intermediate FP risk woman 62.4 (59.1,65.7) 46.5 (44.0,49.0) 66.5 (60.8,72.2) 48.6 (45.3,51.9)
  High FP risk woman 68.7 (65.4,72.0) 52.3 (49.6,55.0) 72.6 (67.1,78.1) 54.4 (50.9,57.9)
  Very high FP risk woman 71.6 (68.1,75.1) 55.1 (52.2,58.0) 75.4 (69.9,80.9) 57.3 (53.6,61.0)
*
False positive (FP) risk profiles are based on multivariable logistic regression models including age, year of first exam, hormone therapy use,
family history of breast cancer, breast density, availability of comparison films, registry, and random radiologist intercepts. Risk profiles have year
of first exam in 1997–1999, no HT and comparison films available at subsequent screenings. Levels were defined as:
Low = no family history of breast cancer, BI-RADS 1 breast density
Intermediate = no family history of breast cancer, BI-RADS 2 breast density
High = no family history of breast cancer, BI-RADS 3 breast density
Very high = family history of breast cancer, BI-RADS 3 breast density
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Table 5
Cumulative Probability and 95% Confidence Interval for False-Positive Biopsy Recommendation after 10
Years of Screening under Four Screening Strategies (Start Age 40 vs. 50; Annual vs. Biennial Screening) by
Radiologist and Woman Risk Level for False Positives.*
Age 40 at first mammogram Age 50 at first mammogram
Annual screener Biennial screener Annual screener Biennial screener
Overall 7.0 (6.1,7.8) 4.8 (4.4,5.2) 9.4 (7.4,11.5) 6.4 (5.6,7.2)
25th Percentile FP risk radiologist
  Low FP risk woman* 3.2 (2.4,4.0) 2.4 (1.8,3.0) 4.8 (3.0,6.6) 3.4 (2.4,4.4)
  Intermediate FP risk woman 5.0 (4.0,6.0) 3.7 (3.1,4.3) 7.3 (4.9,9.7) 5.3 (4.1,6.5)
  High FP risk woman 6.1 (4.9,7.3) 4.5 (3.7,5.3) 9.0 (6.3,11.7) 6.5 (5.1,7.9)
   Very high FP risk woman 7.6 (6.0,9.2) 5.6 (4.6,6.6) 11.1 (7.6,14.6) 8.0 (6.2,9.8)
50th Percentile FP risk radiologist
  Low FP risk woman 3.5 (2.5,4.5) 2.6 (2.0,3.2) 5.2 (3.2,7.2) 3.7 (2.7,4.7)
  Intermediate FP risk woman 5.4 (4.4,6.4) 4.0 (3.2,4.8) 8.0 (5.5,10.5) 5.7 (4.3,7.1)
  High FP risk woman 6.7 (5.3,8.1) 4.9 (4.1,5.7) 9.8 (6.7,12.9) 7.0 (5.4,8.6)
  Very high FP risk woman 8.3 (6.5,10.1) 6.1 (4.9,7.3) 12.1 (8.2,16.0) 8.7 (6.7,10.7)
75th Percentile FP risk radiologist
  Low FP risk woman 4.2 (3.2,5.2) 3.0 (2.2,3.8) 6.1 (3.9,8.3) 4.4 (3.2,5.6)
  Intermediate FP risk woman 6.4 (5.2,7.6) 4.7 (3.9,5.5) 9.4 (6.5,12.3) 6.8 (5.2,8.4)
  High FP risk woman 7.9 (6.3,9.5) 5.8 (4.8,6.8) 11.5 (8.0,15.0) 8.3 (6.5,10.1)
  Very high FP risk woman 9.8 (7.8,11.8) 7.2 (5.8,8.6) 14.1 (9.6,18.6) 10.2 (7.8,12.6)
*
False positive (FP) risk profiles are based on multivariable logistic regression models including age, year of first exam, hormone therapy use,
family history of breast cancer, breast density, availability of comparison films, registry, and random radiologist intercepts. Risk profiles have year
of first exam in 1997–1999, no HT and comparison films available at subsequent screenings. Levels were defined as:
Low = no family history of breast cancer, BI-RADS 1 breast density
Intermediate = no family history of breast cancer, BI-RADS 2 breast density
High = no family history of breast cancer, BI-RADS 3 breast density
Very high = family history of breast cancer, BI-RADS 3 breast density
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